Tadocizumab

CAS No. 339086-80-5

Tadocizumab( —— )

Catalog No. M36788 CAS No. 339086-80-5

Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 687 In Stock
10MG 937 In Stock
25MG 1416 In Stock
50MG 1832 In Stock
100MG 2502 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tadocizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
  • Description
    Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    339086-80-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. S Kaku, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996 Apr;75(4):679-84.?
molnova catalog
related products
  • ML165

    A high-affinity, selective platelet integrin αIIbβ3 receptor antagonist with IC50 of 96 nM.

  • CWHM-12

    A novel active RGD peptidomimetic inhibitor of αv integrin with IC50s of 1.8/0.8/61/1.5/0.2 nM for αvβ1/αvβ3/αvβ5/αvβ6/αvβ8; no inhibition on αIIbβ3, α2β1 and α10β1 (>50 uM).

  • Pyrintegrin

    Pyrintegrin is an β1-integrin agonist that promotes embryonic stem cells' survival. Pyrintegrin can be used as a podocyte-protective agent.